PCRX News and Press, Pacira BioSciences Inc. From 09/13/22

Pacira BioSciences ( NASDAQ: PCRX ) stated Tuesday that its preliminary net product sales rose 17.7% sequentially during the month to $59.1M for Aug. 2022; up 108% year-over-year. It includes: EXPAREL net product sales, $46.7M; ZILRETTA sales, $9.7M; and iovera° net p...

-- EXPAREL average daily sales for August 2022 were 108 percent of August 2021 – -- More than 11 million patients have received EXPAREL since launch -- TAMPA, Fla., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commit...

Pacira BioSciences ( NASDAQ: PCRX ), a company focused on non-opioid pain management, announced Wednesday that leading therapy Exparel reached the primary endpoint in a Phase 3 trial allowing the company to seek label expansion for the local anesthetic. The randomized trial ...

TAMPA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced positive topline results from its Phase 3 study of EXPAREL as a single-dose femoral...

Summary John Paulson’s 13F portfolio value decreased from $3.25B to $2.03B this quarter. Paulson & Company dropped SPDR Gold ETF and Exxon Mobil while increasing Horizon Therapeutics. The top three positions are at 43% of the portfolio. This article is part of...

Growing since 2016 among the healthcare industry’s opioid-aversion concerns, on a multi-markets basis. Institutions hold 110% of shares, insiders only 1%. Institutions know that owning the stock previously when its Reward/Risk ratio was like today’s it took profits 7...

Pacira BioSciences ( NASDAQ: PCRX ) reported Wednesday its preliminary product sales of $50.2M for July 2022, almost flat on year-on-year basis. It includes: EXPAREL net product sales, $40.9M; ZILRETTA sales, $8.2M; and iovera° net product sales, $1.1M. The compan...

-- EXPAREL average daily sales for July 2022 were 105 percent of July 2021 -- TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported p...

Baillie Gifford’s 13F portfolio value decreased from ~$143B to ~$97.51B this quarter. They increased Spotify and Royalty Pharma while decreasing Cloudflare, Petrobras, BeiGene, CBRE Group, Teladoc, and Peloton Interactive. The top three positions are Moderna, Tesla Motors, ...

TAMPA, Fla. and MOUNT LAUREL, N.J., Aug. 09, 2022 (GLOBE NEWSWIRE) -- The National Football League Alumni Association (NFLA), the oldest, most well-known and well-respected retired player organization in professional sports, and Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader i...